About TRIGR Therapeutics
TRIGR Therapeutics is a Healthcare company based in Irvine (United States) founded in 2018, and was acquired by Compass Therapeutics in May 2021. Small molecule therapeutics for cancer are developed by the company. TRIGR Therapeutics has raised $5 million across 1 funding round from investors including Compass Therapeutics and Handok. Its focus areas include Life Sciences, Oncology, Drugs and Diversified. Its competitors include Moderna, BeiGene and Incyte; 2 of its 3 listed competitors have raised funding.
Company details
TRIGR Therapeutics is developing small molecule-based therapeutics for the treatment of cancer. The companys lead product candidate is targeting vascular endothelial growth factor (VEGF) signaling pathway and DLL4 both of which play an important role in vascular development and tumor angiogenesis. It is used for the treatment of gastric cancer and other solid tumors and is Phase 1 clinical trials. The company is also developing other products for the treatment of multiple myeloma and other solid tumors.
- Headquarters Irvine, United States
- Stage Acquired
- SectorsHealthcare
- Website ww38.trigrrx.com
- Acquired by Compass Therapeutics (May 2021)
- Total Equity Funding$5M (USD)
in 1 rounds
- Latest Funding Round$5M (USD), Series A
Apr 2019
- InvestorsCompass Therapeutics
& 1 more
- Acquired byCompass Therapeutics
(May 2021)
Funding Insights of TRIGR Therapeutics
TRIGR Therapeutics has successfully raised a total of $5M through 1 strategic funding round. The most recent funding activity was a Series A round of $5 million completed in April 2019. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $5M
- Total Rounds 1
- Last Round Series A — $5M
- First Round $5M
(Apr 2019)
- Investors Count 1
All 1 funding rounds of TRIGR Therapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Apr 2019 | $5M | Series A | – | Handok | – |
2 investors in total: 2 institutional.
Investors in TRIGR Therapeutics
TRIGR Therapeutics has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include Compass Therapeutics and Handok.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Pharmaceuticals, medical devices, and healthcare products are developed and marketed. | 1954 | handok.co.kr | Seoul, South Korea | |
Therapeutic antibodies for cancer treatment are discovered and developed. | 2013 | compasstherapeutics.com | Cambridge, United States |
Investor details for TRIGR Therapeutics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of TRIGR Therapeutics
3 dated milestones of TRIGR Therapeutics across 3 years, from founding to its latest funding, stage changes and deals.
- Founded TRIGR Therapeutics is founded.
- Funding First funding round of $5.0M.
- Exit Acquired by Compass Therapeutics.
Competitors of TRIGR Therapeutics
TRIGR Therapeutics has 3 listed competitors in our database, 2 of them funded. They include Moderna, BeiGene and Incyte.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| modernatx.com | 2010 | Cambridge, United States | $2.78B | 1,312 | mRNA-based therapeutics for diseases including cancer and infections are developed. | |
| beigene.com | 2010 | Cambridge, United States | $172M | 1,090 | Targeted and immune-oncology drugs for cancer treatment are developed. | |
| incyte.com | 1991 | Wilmington, United States | 1,387 | Small molecules are developed for cancer and skin disease treatments. |
Detailed competitors of TRIGR Therapeutics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Oncology
3 companies that operate in the same segment as TRIGR Therapeutics (Oncology) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Trigr Therapeutics
Complete news archive for TRIGR Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about TRIGR Therapeutics
TRIGR Therapeutics was founded in 2018 and raised its 1st funding round 1 year after it was founded.
TRIGR Therapeutics is headquartered in Irvine, United States. It is registered at Irvine, California, United States.
TRIGR Therapeutics is a funded company, having raised a total of $5M across 1 funding round to date. The company's 1st funding round was a Series A of $5M, raised on Apr 2019.
TRIGR Therapeutics is developing small molecule-based therapeutics for the treatment of cancer. The companys lead product candidate is targeting vascular endothelial growth factor (VEGF) signaling pathway and DLL4 both of which play an important role in vascular development and tumor angiogenesis. It is used for the treatment of gastric cancer and other solid tumors and is Phase 1 clinical trials. The company is also developing other products for the treatment of multiple myeloma and other solid tumors.
TRIGR Therapeutics has 2 investors. Key investors include Compass Therapeutics, and Handok.
Yes. TRIGR Therapeutics was acquired by Compass Therapeutics in May 2021.